Piramal Pharma Past Earnings Performance
Past criteria checks 0/6
Piramal Pharma's earnings have been declining at an average annual rate of -142.5%, while the Pharmaceuticals industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 9.5% per year.
Key information
-142.5%
Earnings growth rate
-170.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 9.5% |
| Return on equity | -0.4% |
| Net Margin | -0.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26
Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Revenue & Expenses BreakdownBeta
How Piramal Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 78,435 | -333 | 22,171 | 0 |
| 30 Sep 23 | 76,009 | -1,336 | 21,856 | 0 |
| 30 Jun 23 | 74,096 | -1,760 | 21,396 | 0 |
| 31 Mar 23 | 71,427 | -1,865 | 21,046 | 0 |
| 31 Dec 22 | 72,228 | -325 | 20,064 | 0 |
| 30 Sep 22 | 69,535 | 2,210 | 1,409 | 0 |
| 30 Jun 22 | 67,532 | 2,626 | 16,545 | 0 |
| 31 Mar 22 | 67,341 | 3,760 | 15,888 | 0 |
| 31 Mar 21 | 58,868 | 7,708 | 14,762 | 0 |
Quality Earnings: PPLPHARMA is currently unprofitable.
Growing Profit Margin: PPLPHARMA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PPLPHARMA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PPLPHARMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PPLPHARMA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: PPLPHARMA has a negative Return on Equity (-0.43%), as it is currently unprofitable.